Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
372 studies found for:    "Squamous cell carcinoma of the head and neck"
Show Display Options
Rank Status Study
1 Terminated EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
2 Completed
Has Results
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab;   Drug: EMD 1201081
3 Completed Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
4 Recruiting Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Plasma samples
5 Completed Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Erlotinib chlorhydrate;   Drug: Cisplatin;   Procedure: Radiation therapy
6 Terminated Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: temsirolimus;   Drug: cisplatin;   Drug: cetuximab
7 Completed Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: dacomitinib;   Radiation: Radiotherapy;   Drug: Cisplatin
8 Unknown  MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Biological: MAGE-A3;   Biological: HPV-16 vaccine
9 Active, not recruiting Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Cetuximab and stereotactic radiosurgery
10 Completed Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cabazitaxel;   Drug: Methotrexate
11 Completed
Has Results
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Cetuximab + concomitant boost radiotherapy
12 Completed
Has Results
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Drug: Cisplatin/Carboplatin;   Drug: 5-Fluorouracil
13 Not yet recruiting Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Avelumab;   Other: Chemoradiation
14 Unknown  E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Condition: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: E7050;   Drug: Cetuximab
15 Completed Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Bevacizumab;   Drug: erlotinib;   Drug: Sulindac
16 Terminated
Has Results
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: AT-101;   Drug: Docetaxel
17 Not yet recruiting PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Conditions: Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma
Interventions: Drug: Pembrolizumab;   Radiation: Radiotherapy;   Drug: Chemotherapy
18 Unknown  Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Cetuximab
19 Recruiting Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cisplatin;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
20 Withdrawn Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Condition: Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Interventions: Drug: sorafenib;   Drug: sorafenib and cisplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.